Andropause Symptoms: When to See a Doctor

What Is Andropause and Why Does It Happen?

Andropause refers to the gradual decline of testosterone and other androgens in aging men, producing a cluster of physical, sexual, and psychological symptoms. Unlike menopause in women, which involves a sharp drop in estrogen over a few years, andropause unfolds over decades with testosterone falling at roughly 1-2% per year after age 30.

The Endocrine Society defines male hypogonadism as a total testosterone level below 300 ng/dL (10.4 nmol/L) confirmed on at least two morning blood draws. The hypothalamic-pituitary-gonadal (HPG) axis drives testosterone production. As men age, Leydig cells in the testes become less responsive to luteinizing hormone (LH), and the hypothalamus loses some of its pulsatile GnRH signaling. Both changes contribute to lower circulating testosterone.

The European Male Ageing Study (EMAS), which followed 3,369 men aged 40 to 79 across eight European centers, found that only 2.1% met strict criteria for late-onset hypogonadism when requiring both low testosterone and at least three sexual symptoms. That number is lower than many popular-press estimates suggest. The discrepancy matters: not every man with fatigue or reduced energy after 40 has clinically low testosterone.

Several factors accelerate the decline. Obesity is the strongest modifiable risk factor. The Massachusetts Male Aging Study (MMAS) showed that a 4-5 point increase in BMI produced a testosterone decrease comparable to 10 years of aging. Type 2 diabetes, chronic opioid use, obstructive sleep apnea, and heavy alcohol intake also suppress the HPG axis independently of age.

Recognizing the Symptoms That Matter

The symptoms of andropause overlap with those of depression, thyroid disease, sleep disorders, and simple deconditioning. That overlap is precisely why a medical evaluation matters. Attributing everything to "getting older" can delay diagnosis of a treatable condition.

Sexual symptoms tend to be the most specific. The EMAS study identified three symptoms that most reliably correlated with biochemically confirmed low testosterone: erectile dysfunction, reduced frequency of morning erections, and low sexual desire. When all three were present alongside a total testosterone below 320 ng/dL, the positive predictive value for LOH exceeded 80%.

Physical symptoms include decreased muscle mass and strength, increased body fat (particularly visceral fat), reduced bone mineral density, and fatigue that does not improve with rest. A prospective cohort from the Concord Health and Ageing in Men Project found that men in the lowest testosterone quintile had a 33% higher risk of falls compared to those in the highest.

Psychological symptoms can be the most distressing. Irritability, difficulty concentrating, depressed mood, and a vague sense of diminished vitality are common complaints. The Testosterone Trials (TTrials), a coordinated set of seven randomized controlled studies enrolling 790 men aged 65 and older, reported that testosterone gel modestly improved mood as measured by the PHQ-9 compared to placebo, though the effect size was smaller than what antidepressants typically produce.

Sleep disturbances deserve separate attention. Low testosterone is associated with increased frequency of nocturnal awakenings and reduced slow-wave sleep. At the same time, obstructive sleep apnea, which is common in overweight middle-aged men, independently suppresses testosterone. This bidirectional relationship means that treating sleep apnea alone can raise testosterone by 2-3 nmol/L in some men.

When to See a Doctor: Red Flags and Decision Points

Not every man over 40 with occasional fatigue needs a testosterone test. But certain patterns should prompt an evaluation.

Schedule an appointment if sexual dysfunction persists for more than four weeks. Erectile dysfunction in men under 50 warrants evaluation regardless of suspected testosterone status, because it is an independent cardiovascular risk marker. The Princeton III Consensus panel recommends that men with ED and no cardiac symptoms undergo cardiovascular risk stratification before or alongside any hormonal workup.

Seek evaluation if you notice breast tenderness or breast tissue growth (gynecomastia), which can signal an abnormal testosterone-to-estradiol ratio. Rapid-onset gynecomastia in a man over 50 also requires ruling out testicular or adrenal tumors.

Depression-like symptoms that do not respond to first-line treatment deserve a testosterone check. A 2019 meta-analysis of 27 RCTs (N = 1,890) published in JAMA Psychiatry found that testosterone therapy had a moderate antidepressant effect (effect size 0.21 to 95% CI 0.10 to 0.32), especially in men with baseline hypogonadism.

Unexplained anemia is another underappreciated sign. The TTrials demonstrated that testosterone gel corrected unexplained anemia in 54% of hypogonadal men compared to 15% on placebo over 12 months. If your doctor finds a hemoglobin below 12.5 g/dL without an obvious cause, checking testosterone is appropriate.

Bone fractures from minimal trauma in men over 50 should trigger a workup. The Endocrine Society recommends testosterone measurement in all men being evaluated for osteoporosis.

Dr. Shalender Bhasin, principal investigator of the TTrials and professor at Harvard Medical School, has stated: "The diagnosis of hypogonadism requires both consistently low testosterone levels and clear symptoms. Neither criterion alone is sufficient."

How Andropause Is Diagnosed

Diagnosis follows a structured approach. The Endocrine Society's 2018 Clinical Practice Guideline outlines the standard pathway.

Step one is symptom screening. The ADAM questionnaire is a 10-item yes/no tool. A positive screen (answering yes to questions 1 or 7, or to any three other questions) has a sensitivity of about 88%, though specificity is lower at around 60%. It is useful as a starting point but not as a standalone diagnostic.

Step two is morning blood work. Total testosterone must be drawn between 7:00 and 10:00 AM, when levels are highest. A single low result is not diagnostic. The Endocrine Society requires confirmation with a second draw on a separate day before labeling a man hypogonadal.

If total testosterone falls between 200 and 400 ng/dL, the next step is measuring free testosterone or bioavailable testosterone. Sex hormone-binding globulin (SHBG) rises with age, binding more testosterone and reducing the biologically active fraction. Men with borderline total testosterone but low calculated free testosterone (below 6.5 ng/dL by equilibrium dialysis) may still have clinically meaningful hypogonadism.

Step three distinguishes primary from secondary hypogonadism by checking LH and FSH. Elevated gonadotropins (LH above 9.4 IU/L) indicate primary testicular failure. Normal or low gonadotropins with low testosterone point to a hypothalamic-pituitary cause, which requires further evaluation with prolactin, iron studies (to rule out hemochromatosis), and potentially pituitary MRI.

Additional baseline labs include a complete blood count (hematocrit is essential before starting TRT), PSA, lipid panel, hemoglobin A1c, and estradiol. The Endocrine Society recommends against screening asymptomatic men or men with acute illness, as both states can transiently suppress testosterone.

Dr. Abraham Morgentaler, associate clinical professor at Harvard Medical School, has noted: "We frequently see men whose testosterone was checked during a hospitalization or acute illness and found to be low. These results are unreliable and should always be repeated when the patient has recovered."

Causes Beyond Normal Aging

While age-related HPG axis decline accounts for many cases, specific medical conditions can accelerate or mimic andropause.

Obesity is the single largest driver. Adipose tissue expresses aromatase, which converts testosterone to estradiol. A cross-sectional analysis from NHANES III showed that each 1-unit increase in BMI was associated with a 2% decrease in total testosterone. Weight loss alone can raise testosterone levels significantly: a meta-analysis of 24 studies found that men who lost weight through diet and exercise increased their testosterone by an average of 2.9 nmol/L.

Type 2 diabetes and metabolic syndrome are strongly associated with low testosterone. The relationship is bidirectional. Low testosterone predicts incident diabetes, and diabetes suppresses testosterone production. The TIMES2 study showed that testosterone replacement improved insulin resistance (HOMA-IR) by 15.2% in hypogonadal men with type 2 diabetes over 12 months.

Chronic opioid therapy is a frequently overlooked cause. Opioids suppress GnRH pulsatility. Studies report that 75% of men on long-term opioids have subnormal testosterone, a condition sometimes called opioid-induced androgen deficiency (OPIAD).

Other secondary causes include hyperprolactinemia, hemochromatosis (iron overload affecting the pituitary), Klinefelter syndrome (47,XXY), prior chemotherapy or radiation, traumatic brain injury affecting the pituitary, and chronic glucocorticoid use. Anabolic steroid use, even years prior, can suppress the HPG axis for months to years after discontinuation.

Treatment Options for Confirmed Andropause

Once the diagnosis is established with two low morning testosterone values and concordant symptoms, treatment discussions should begin.

Testosterone replacement therapy (TRT) is the primary pharmacologic intervention for confirmed hypogonadism. The Endocrine Society recommends against TRT in men who are actively trying to conceive, as exogenous testosterone suppresses spermatogenesis through negative feedback on LH and FSH.

Common TRT formulations include intramuscular testosterone cypionate or enanthate (100-200 mg every 1-2 weeks), transdermal gels (1% or 1.62%, applied daily), transdermal patches, subcutaneous pellets (implanted every 3-6 months), and nasal testosterone (Natesto, dosed three times daily). Injectable forms are the least expensive, typically $30-80 per month for generic testosterone cypionate. Gels cost $200-500 per month without insurance.

Expected timelines for improvement vary by symptom domain. A review published in the European Journal of Endocrinology mapped the trajectory: libido improvements appear within 3-6 weeks, with a plateau at 6 months. Erectile function may take up to 6 months to respond fully, and some men require phosphodiesterase-5 inhibitors (such as sildenafil or tadalafil) as adjuncts. Body composition changes, including increased lean mass and decreased fat mass, become measurable at 12-16 weeks and continue for 1-2 years. Mood and energy improvements typically occur within 3-6 weeks.

Monitoring during TRT is non-negotiable. The Endocrine Society recommends checking testosterone levels, hematocrit, and PSA at 3 months, 6 months, and then annually. Hematocrit above 54% requires dose reduction or temporary cessation, as polycythemia increases thrombotic risk. PSA should be evaluated in the context of age-specific norms; a confirmed rise above 4.0 ng/mL or a velocity exceeding 1.4 ng/mL/year warrants urology referral.

For men who want to preserve fertility, alternatives to TRT include clomiphene citrate (25-50 mg daily, off-label), which stimulates endogenous testosterone production through selective estrogen receptor modulation at the hypothalamus. A retrospective review of 86 hypogonadal men treated with clomiphene showed a mean testosterone increase from 228 to 612 ng/dL while maintaining sperm parameters. Human chorionic gonadotropin (hCG), typically dosed at 1,500-3 to 000 IU two to three times weekly, is another option that stimulates Leydig cells directly.

Lifestyle Interventions That Move the Needle

Lifestyle modification should accompany, and in mild cases precede, pharmacologic treatment.

Resistance training has the strongest evidence base. A 12-week randomized trial of progressive resistance exercise in men aged 60-75 found significant increases in total and free testosterone compared to sedentary controls. Compound movements (squats, deadlifts, rows) performed at 70-85% of one-rep max, 3-4 sets per exercise, and 3-4 sessions per week, produce the most reliable hormonal response.

Sleep optimization is underrated. Testosterone is secreted in a circadian pattern linked to sleep onset. A University of Chicago study restricted healthy young men to five hours of sleep for one week and found daytime testosterone levels dropped by 10-15%, equivalent to 10-15 years of aging.

Weight loss directly raises testosterone. The EMAS found that losing 10% of body weight was associated with a testosterone increase of approximately 2.9 nmol/L. For overweight men with borderline-low testosterone, weight reduction through caloric deficit and increased activity may push levels above the symptomatic threshold without TRT.

Alcohol moderation matters. Chronic heavy drinking suppresses testosterone through multiple mechanisms: direct Leydig cell toxicity, increased hepatic SHBG production, and hypothalamic GnRH disruption. Reducing intake to fewer than 14 standard drinks per week aligns with both cardiovascular guidelines and endocrine health.

What the Latest Evidence Says About Long-Term TRT Safety

Cardiovascular safety was the largest unanswered question in TRT until recently. The TRAVERSE trial, a randomized, double-blind, placebo-controlled study enrolling 5,246 men aged 45-80 with hypogonadism and established or high-risk cardiovascular disease, provided the clearest answer to date. Published in the New England Journal of Medicine in 2023, TRAVERSE showed that testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a mean follow-up of 33 months (hazard ratio 0.96 to 95% CI 0.78-1.17).

Prostate safety data from TRAVERSE were similarly reassuring. The rate of prostate cancer was not significantly different between testosterone and placebo groups. This finding aligns with earlier meta-analyses that found no increased prostate cancer incidence with TRT over study durations of 6-36 months. The Endocrine Society still recommends against TRT in men with active prostate or breast cancer.

Bone health benefits are well documented. The TTrials bone substudy showed that testosterone gel increased volumetric bone mineral density and estimated bone strength of the spine and hip in hypogonadal men over 12 months, with the greatest gains in trabecular bone.

Venous thromboembolism remains a concern. TRAVERSE noted a numerically higher rate of pulmonary embolism in the testosterone group (0.9% vs. 0.5%), though the overall rate of venous thromboembolic events was not statistically significant. Monitoring hematocrit remains the standard safety practice.